Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
December 01 2021 - 4:15PM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™ for the treatment of cancer and autoimmune
diseases, today announced that it will host a virtual investor and
analyst event focused on the company’s RED PLATFORM® and
preclinical pipeline in oncology and autoimmunity, in particular
type 1 diabetes. The event will be held from 11:00 a.m. to 1:00
p.m. ET on Thursday, December 16, 2021. This will be the first of a
series of investor and analyst events that the company plans to
host periodically.
The event will feature presentations from Rubius management,
providing an overview of the Company’s RED PLATFORM® and the
translation of the platform into a pipeline of preclinical programs
in oncology and autoimmune diseases. In addition, Dr. Gerald T.
Nepom, M.D., PhD., will provide an overview of the current and
emerging treatment landscape and unmet needs in type 1 diabetes.
Dr. Nepom is the Director of the Immune Tolerance Network,
sponsored by the National Institutes of Health, and former Director
and founder of the Benaroya Research Institute, in Seattle WA,
USA. His primary research interests focus on CD4 T cell response in
autoimmunity, with an emphasis on type 1 diabetes, as well as the
translation of immunological intervention strategies into
innovative clinical trials. The Rubius management team and Dr.
Nepom will host a Q&A session following the presentations.
A live audio webcast will be available within the Investors
& Media section of the Rubius Therapeutics website. An archived
replay will be accessible for 90 days following the event.
About Rubius TherapeuticsRubius
Therapeutics is a clinical-stage biopharmaceutical company
developing a new class of medicines called Red Cell Therapeutics™.
The Company’s proprietary RED PLATFORM® was designed to genetically
engineer and culture Red Cell Therapeutics™ that are selective,
potent and off-the-shelf allogeneic cellular therapies for the
potential treatment of several diseases across multiple therapeutic
areas. Rubius’ initial focus is to advance RCT™ product candidates
for the treatment of cancer and autoimmune diseases by leveraging
two distinct therapeutic modalities — potent cell-cell interaction
and tolerance induction. Rubius Therapeutics was named among
the 2020 Top Places to Work in Massachusetts by the Boston Globe,
and its manufacturing site was recently named 2021 Best
Places to Work in Rhode Island by Providence Business News.
For more information, visit www.rubiustx.com, follow us on Twitter
or LinkedIn or like us on Facebook.
Contacts:InvestorsElhan Webb,
CFA, VP Investor Relationselhan.webb@rubiustx.com
MediaMarissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2023 to Apr 2024